Lonza Group Ag (OTCMKTS:LZAGY) Short Interest Update

Lonza Group Ag (OTCMKTS:LZAGY) saw a large growth in short interest in March. As of March 31st, there was short interest totaling 5,253 shares, a growth of 34.6% from the March 15th total of 3,903 shares. Based on an average daily trading volume, of 171,137 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

LZAGY has been the topic of a number of research analyst reports. Royal Bank Of Canada raised Lonza Group from a “hold” rating to a “moderate buy” rating in a report on Wednesday, February 11th. Zacks Research upgraded shares of Lonza Group from a “strong sell” rating to a “hold” rating in a report on Wednesday, April 8th. One investment analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy”.

Lonza Group Price Performance

Shares of OTCMKTS LZAGY opened at $67.79 on Friday. The company has a quick ratio of 1.77, a current ratio of 2.24 and a debt-to-equity ratio of 0.42. Lonza Group has a 12 month low of $58.53 and a 12 month high of $73.85. The business has a fifty day simple moving average of $65.03 and a 200-day simple moving average of $67.08.

About Lonza Group

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.